Expression of Bax Protein as A Prognosis Factor of Radiotherapy Response to Decreased Tumor Size in Stage IIB-IIIB Cervical Cancer
DOI:
https://doi.org/10.26911/thejmch.2022.07.03.07Abstract
Background: Cervical cancer plays a role as the leading cause of cancer death for women in developing countries. Radiation therapy kills cancer cells through double strand breaks and the apoptotic process. Bax protein is one of the regulators of apoptosis. This study analyzed the role of Bax expression as a prognostic factor in radiation therapy response in reducing tumor size in patients with advanced cervical cancer (IIB-IIIB).
Subjects and Method: This research is a retrospective cohort observational analytic study from January 2021 to April 2021 in the Department of Obstetrics and Gynecology in collaboration with the Department of Anatomical Pathology, Dr. Moewardi Hospital, Surakarta, Indonesia. This study involved 30 cervical cancer stage IIB-IIIB patients. The level of Bax expression was determined by immunohistochemical examination. ROC curve analysis was used to find cut-off points and evaluate the sensitivity and specificity of Bax in the prognosis of radiotherapy in patients with advanced cervical cancer (IIB-IIIB). Chi square test was used to determine the relationship between Bax expression and changes in tumor size in cervical cancer patients.
Results: The ROC curve analysis showed that the AUC Bax score in prognosis of radiation therapy was 0.575 (CI 95%= 0.32 to 0.83) and the cutoff point was 62.5%. Based on the analysis of the ROC curve, the Bax expression of 62.5% shows a sensitivity of 56.5% and a specificity of 71.4%. Analysis of the relationship between Bax protein expression on changes in tumor size using the Chi Square test showed a P value of 0.390 (p> 0.05).
Conclusion: The expression of Bax protein cannot play a role as a prognostic factor in the response of radiation therapy to the reduction in tumor size in stage IIB-IIIB uterine cervical cancer.
Keywords:
bax, radiotherapy, cervical cancerReferences
Ayatollahi H, Sharifi N, Sadeghian MH, Alenabi A, Ghasemian-Moghadam HR (2014). Immunohistochemical expression of apoptosis regulators in squamous cell carcinoma of the cervix and their association with human papillomavirus 16/18 subtypes. Balkan Medical Journal. AVES Ibrahim Kara. 31(3): 202–207. doi: 10.5152/Balkanmedj.2014.13175.
Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR (2010). The BCL-2 family reunion. Mol Cell. 299–310. doi: 10.1016/j.molcel.2010.01.025.
Cohen PA, Jhingran A, Oaknin A, Denny L (2019). Cervical cancer. The Lancet. Lancet Publishing Group. 169–182. doi:10.1016/S01406736(18)32470X.
Czabotar PE, Lessene G, Strasser A, Adams JM (2014). Control of apoptosis by the BCL-2 protein family: Implications for physiology and therapy. Nat Rev Mol Cell Biol. 49–63. doi: 10.1038/nrm3722.
Edlich F, Banerjee S, Suzuki M, Cleland M M, Arnoult D, Wang C, Neutzner A, et al. (2011). Bcl-xL retrotranslocates Bax from the mitochondria into the cytosol. Cell. Elsevier B.V. 145(1): 104-116. doi: 10.1016/j.cell.2011.02.034.
Murti B (2013). Desain dan ukuran sampel untuk penelitian kuantitatif dan kualitatif di bidang kesehatan (Design and sample size for quantitative and qualitative research in health) 3rd edn. Yogyakarta: Gajah Mada University Press.
Naseri MH, Mahdavi M, Davoodi J, Tackallou HS, Goudarzvand M, Neishabouri SH (2015). Up regulation of Bax and down regulation of Bcl2 during 3-NC mediated apoptosis in human cancer cells. Cancer Cell International. BioMed Central Ltd. 15(1): 55. doi: 10.1186/s1293501502042.
Oh JM, Kim SH, Lee YL, Seo M, Kim SY, Song YS, Kim WH, et al. (2009). Human papillomavirus E5 protein induces expression of the EP4 subtype of prostaglandin E2 receptor in cyclic AMP response element-dependent pathways in cervical cancer cells. Carcinogenesis. Carcinogenesis. 30(1): 141–149. doi: 10.1093/carcin/bgn236.
Oh JM, Kim SH, Cho EA, Song YS, Kim WH, Juhnn YS (2010). Human papillomavirus type 16 E5 protein inhibits hydrogen peroxide-induced apoptosis by stimulating ubiquitin-proteasome-mediated degradation of Bax in hu-man cervical cancer cells. Carcinogenesis. Oxford Academic. 31(3). 402–410. doi: 10.1093/carcin/bgp318.
Peña‐Blanco A, García‐Sáez AJ (2018). Bax, Bak and beyond-mitochondrial performance in apoptosis. The FEBS Journal. Blackwell Publishing Ltd, 285 (3): 416–431. doi: 10.1111/febs.14186.
Safari S, Baratloo A, Elfil M, Negida A (2016). Evidence based emergency medicine; Part 5 receiver operating curve and area under the curve. Emergency (Tehran, Iran). Shahid Beheshti University of Medical Sciences. 4(2): 111–3. doi: 10.22037/emergency.v4i2.11903.
Schellenberg B, Wang P, Keeble JA, Rodriguez-Enriquez R, Walker S, Owens TW, Foster F, et al. (2013). Bax exists in a dynamic equilibrium between the cytosol and mitochondria to control apoptotic priming. Molecular Cell. Cell Press. 49(5): 959–971. doi: 10.1016/j.molcel.2012.12.022.
Strasser A, Cory S, Adams JM (2011). Deciphering the rules of programmed cell death to improve therapy of cancer and other diseases. EMBO J. 3667–3683. doi: 10.1038/emboj.2011.307.
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. Wiley. doi: 10.3322/caac.21660.
Tait SWG, Green DR (2010). Mitochondria and cell death: Outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol: 621–632. doi: 10.1038/nrm2952.
Todt F, Cakir Z, Reichenbach F, Emschermann F, Lauterwasser J, Kaiser A, Ichim G, et al. (2015). Differential retrotranslocation of mitochondrial Bax and Bak. The EMBO Journal. 34(1): 67–80. doi: 10.15252/embj.201488806.
Udiyanto H, Mudigdo A, Sulistyowati S, Purwanto B, Widyaningsih V, Wasita B (2020). A Cohort Study: caspase-3 as prognostic factor of radiation therapy in the advanced stage of cervical cancer (IIB-IIIB) patients. 9(2): 501–503. doi: 10.15562/bmj.v9i2.1783.
